HRP20180659T1 - Disperzija amorfne krutine, namijenjena upotrebi u liječenju raka na mozgu - Google Patents

Disperzija amorfne krutine, namijenjena upotrebi u liječenju raka na mozgu

Info

Publication number
HRP20180659T1
HRP20180659T1 HRP20180659TT HRP20180659T HRP20180659T1 HR P20180659 T1 HRP20180659 T1 HR P20180659T1 HR P20180659T T HRP20180659T T HR P20180659TT HR P20180659 T HRP20180659 T HR P20180659T HR P20180659 T1 HRP20180659 T1 HR P20180659T1
Authority
HR
Croatia
Prior art keywords
treatment
solid dispersion
amorphous solid
brain cancer
brain
Prior art date
Application number
HRP20180659TT
Other languages
English (en)
Inventor
Patrice A. Lee
Shannon L. Winski
Kevin Koch
Original Assignee
Array Biopharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48048296&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20180659(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Array Biopharma, Inc. filed Critical Array Biopharma, Inc.
Publication of HRP20180659T1 publication Critical patent/HRP20180659T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
HRP20180659TT 2012-03-23 2018-04-25 Disperzija amorfne krutine, namijenjena upotrebi u liječenju raka na mozgu HRP20180659T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261615082P 2012-03-23 2012-03-23
EP13714497.8A EP2827900B1 (en) 2012-03-23 2013-03-25 Amorphous solid dispersion for use in the treatment of brain cancer
PCT/US2013/033751 WO2013142875A1 (en) 2012-03-23 2013-03-25 Treatment of brain cancer

Publications (1)

Publication Number Publication Date
HRP20180659T1 true HRP20180659T1 (hr) 2018-06-01

Family

ID=48048296

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20180659TT HRP20180659T1 (hr) 2012-03-23 2018-04-25 Disperzija amorfne krutine, namijenjena upotrebi u liječenju raka na mozgu

Country Status (30)

Country Link
US (3) US20150110780A1 (hr)
EP (4) EP4252855A3 (hr)
JP (6) JP2015514075A (hr)
KR (3) KR102160462B1 (hr)
CN (2) CN109223791A (hr)
AU (4) AU2013234921A1 (hr)
CA (1) CA2867723C (hr)
CL (1) CL2014002497A1 (hr)
CO (1) CO7071139A2 (hr)
CY (2) CY1120204T1 (hr)
DK (2) DK3400943T3 (hr)
ES (2) ES2673165T3 (hr)
HK (1) HK1206276A1 (hr)
HR (1) HRP20180659T1 (hr)
HU (2) HUE053156T2 (hr)
IL (3) IL234627B (hr)
LT (1) LT2827900T (hr)
MX (1) MX354024B (hr)
MY (2) MY202114A (hr)
NZ (4) NZ724544A (hr)
PH (1) PH12014502032A1 (hr)
PL (2) PL3400943T3 (hr)
PT (2) PT3400943T (hr)
RS (1) RS57140B1 (hr)
RU (2) RU2018138976A (hr)
SG (1) SG11201405954YA (hr)
SI (2) SI2827900T1 (hr)
TR (1) TR201808450T4 (hr)
UA (1) UA122044C2 (hr)
WO (1) WO2013142875A1 (hr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122020010643B1 (pt) 2011-10-14 2022-05-17 Array Biopharma Inc Dispersão sólida, composições farmacêuticas compreendendo a referida dispersão, usos das composições farmacêuticas e processo de preparação de uma dispersão sólida
WO2013056183A1 (en) 2011-10-14 2013-04-18 Array Biopharma Inc. Polymorphs of arry-380, a selective herb2 inhibitor and pharmaceutical compositions contianing them
NZ724544A (en) 2012-03-23 2018-05-25 Array Biopharma Inc Treatment of brain cancer
US11078272B2 (en) 2017-03-09 2021-08-03 The Board Of Trustees Of The Leland Stanford Junior University Treatment of pediatric brain tumors with targeting of CD47 pathway
CN111032082A (zh) 2017-04-28 2020-04-17 西雅图基因公司 Her2阳性癌症的治疗
CA3089630A1 (en) 2018-01-31 2019-08-08 Deciphera Pharmaceuticals, Llc Combination therapy for the treatment of mastocytosis
SG11202007198WA (en) 2018-01-31 2020-08-28 Deciphera Pharmaceuticals Llc Combination therapy for the treatment of gastrointestinal stromal tumors
CN112566665A (zh) * 2018-04-09 2021-03-26 莫舍·吉拉迪 用TTFields和Aurora激酶抑制剂治疗肿瘤
CN109942576B (zh) * 2019-03-07 2020-09-11 上海工程技术大学 Irbinitinib及中间体的制备方法
CN111825604A (zh) * 2019-04-16 2020-10-27 宁波药腾医药科技有限公司 一种图卡替尼及其中间产物的合成方法
MX2022001863A (es) 2019-08-12 2022-05-30 Deciphera Pharmaceuticals Llc Metodos para tratar los tumores del estroma gastrointestinal.
DK4084778T3 (da) 2019-12-30 2023-12-11 Deciphera Pharmaceuticals Llc Amorfe kinaseinhibitorformuleringer og fremgangsmåder til anvendelse deraf
KR20220123058A (ko) 2019-12-30 2022-09-05 데시페라 파마슈티칼스, 엘엘씨. 1-(4-브로모-5-(1-에틸-7-(메틸아미노)-2-옥소-1,2-디히드로-1,6-나프티리딘-3-일)-2-플루오로페닐)-3-페닐우레아의 조성물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH690163A5 (fr) * 1995-07-28 2000-05-31 Symphar Sa Dérivés gem-diphosphonates substitués utiles en tant qu'agents anti-cancers.
US6350786B1 (en) * 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
RU2255765C2 (ru) * 2000-01-21 2005-07-10 Чилдренз Хоспитал Лос-Анджелес Способ ингибирования роста опухолей головного мозга с помощью отобранных антагонистов интегринов
AU2001275107A1 (en) 2000-05-30 2001-12-11 Virginia Commonwealth University Vitamin d3 analogs as radiosensitizers for the treatment of cancer
US7452895B2 (en) 2003-08-14 2008-11-18 Array Biopharma Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
CN1989112A (zh) * 2004-06-03 2007-06-27 史密丝克莱恩比彻姆（科克）有限公司 癌症治疗方法
KR20070030240A (ko) 2004-06-03 2007-03-15 스미스클라인 비이참 (코르크) 리미티드 암 치료 방법
ZA200804498B (en) 2005-11-15 2009-07-29 Array Biopharma Inc N4-phenyl-quinazoline-4 -amine derivatives and related compounds as ERBB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
JP5068270B2 (ja) 2006-01-31 2012-11-07 ノバルティス アーゲー 癌を処置するためのｉｌ−１７アンタゴニスト抗体
CA2700673A1 (en) * 2007-09-24 2009-04-02 Tragara Pharmaceuticals, Inc. Therapies for treating cancer using combinations of cox-2 inhibitors and anti-her2(erbb2) antibodies or combinations of cox-2 inhibitors and her2(erbb2) receptor tyrosine kinase inhibitors
US8663643B2 (en) 2008-03-18 2014-03-04 Genentech, Inc. Combinations of an anti-HER2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
BR122020010643B1 (pt) 2011-10-14 2022-05-17 Array Biopharma Inc Dispersão sólida, composições farmacêuticas compreendendo a referida dispersão, usos das composições farmacêuticas e processo de preparação de uma dispersão sólida
WO2013056183A1 (en) 2011-10-14 2013-04-18 Array Biopharma Inc. Polymorphs of arry-380, a selective herb2 inhibitor and pharmaceutical compositions contianing them
NZ724544A (en) 2012-03-23 2018-05-25 Array Biopharma Inc Treatment of brain cancer

Also Published As

Publication number Publication date
EP4252855A2 (en) 2023-10-04
NZ756264A (en) 2022-09-30
CO7071139A2 (es) 2014-09-30
ES2855142T3 (es) 2021-09-23
EP2827900B1 (en) 2018-03-21
SI2827900T1 (en) 2018-06-29
EP4252855A3 (en) 2023-11-15
JP2017141302A (ja) 2017-08-17
KR20200115656A (ko) 2020-10-07
JP7404485B2 (ja) 2023-12-25
US20150110780A1 (en) 2015-04-23
EP2827900A1 (en) 2015-01-28
WO2013142875A1 (en) 2013-09-26
SG11201405954YA (en) 2014-10-30
LT2827900T (lt) 2018-05-10
PL2827900T3 (pl) 2018-08-31
US11504370B2 (en) 2022-11-22
CN104203279A (zh) 2014-12-10
MY174883A (en) 2020-05-20
HUE037966T2 (hu) 2018-09-28
KR20210131426A (ko) 2021-11-02
HUE053156T2 (hu) 2021-06-28
TR201808450T4 (tr) 2018-07-23
RU2018138976A (ru) 2018-12-06
CN104203279B (zh) 2018-10-30
UA122044C2 (uk) 2020-09-10
PT3400943T (pt) 2021-02-02
AU2019203618A1 (en) 2019-06-13
PH12014502032A1 (en) 2014-11-24
AU2013234921A1 (en) 2014-10-02
AU2021261849A1 (en) 2021-12-02
JP2022190126A (ja) 2022-12-22
NZ630843A (en) 2017-01-27
SI3400943T1 (sl) 2021-03-31
MY202114A (en) 2024-04-04
RU2672575C2 (ru) 2018-11-16
KR102317166B1 (ko) 2021-10-26
RS57140B1 (sr) 2018-07-31
RU2014142700A (ru) 2016-05-20
MX2014011437A (es) 2014-11-10
EP3400943B1 (en) 2020-12-02
ES2673165T3 (es) 2018-06-20
DK2827900T3 (en) 2018-05-07
JP2015514075A (ja) 2015-05-18
CN109223791A (zh) 2019-01-18
JP2021178820A (ja) 2021-11-18
AU2019203618B2 (en) 2021-08-05
KR102160462B1 (ko) 2020-09-28
IL269205B (en) 2020-06-30
EP3400943A1 (en) 2018-11-14
KR20140139009A (ko) 2014-12-04
JP2024019526A (ja) 2024-02-09
IL234627B (en) 2018-10-31
CA2867723C (en) 2022-11-08
DK3400943T3 (da) 2021-02-08
US20190255051A1 (en) 2019-08-22
AU2017272232C1 (en) 2019-08-15
IL269205A (en) 2019-11-28
NZ724544A (en) 2018-05-25
US20230190749A1 (en) 2023-06-22
CY1120204T1 (el) 2018-12-12
MX354024B (es) 2018-02-08
AU2017272232B2 (en) 2019-02-28
HK1206276A1 (en) 2016-01-08
PT2827900T (pt) 2018-06-14
KR102490961B1 (ko) 2023-01-19
CL2014002497A1 (es) 2014-11-14
AU2017272232A1 (en) 2018-01-04
PL3400943T3 (pl) 2021-06-14
EP3842044A1 (en) 2021-06-30
IL261659A (en) 2018-10-31
CA2867723A1 (en) 2013-09-26
JP6898960B2 (ja) 2021-07-07
CY1123837T1 (el) 2022-05-27
RU2018138976A3 (hr) 2022-04-08
NZ741615A (en) 2019-10-25
JP2019081792A (ja) 2019-05-30

Similar Documents

Publication Publication Date Title
HRP20180659T1 (hr) Disperzija amorfne krutine, namijenjena upotrebi u liječenju raka na mozgu
HRP20171474T1 (hr) Triazolopirazini kao inhibitori brd4 za uporabu u liječenju raka
HK1209745A1 (en) Compounds and methods for antiviral treatment
EP2819703A4 (en) TREATMENT OF PAIN
GB201115711D0 (en) Phyto-cannabinoids for use in the treatment of cancer
IL238116B (en) A process for preparing compounds for use in the treatment of cancer
ZA201408855B (en) Flocculation treatment agent
HK1212340A1 (en) Substituted indazol pyrrolopyrimidines useful in the treatment of hyperfoliferative disorders
IL239374B (en) Preparations and methods for treating brain tumors
IL235127A (en) Hpn-100 for use in the treatment of nitrogen-related diseases
GB201221123D0 (en) Device for photodynamic treatment
SI2872176T1 (sl) Karboranilporfirin za uporabo pri zdravljenju raka
PL2855475T3 (pl) Alfa-karboliny do leczenia nowotworu
ZA201407164B (en) Device for use in the treatment hyperbilirubinemia